Our Development Focus

  • Our Tunable Drug Conjugates (TDCs) platform combines novel bioorthogonal SiLinker linker chemistries, Payload Cassettes, and DVD-Fab targeting technologies, and represents a unique and potentially disruptive new class of drug conjugate therapeutics. Our initial focus is on the treatment of intractable cancers with other disease indications to follow.

  • Antibody Drug Conjugates (ADCs) represent a distinct class of therapeutics designed to treat diseases by targeting only tissues bearing a distinct marker or receptor. ADCs comprise antibodies equipped with cytotoxic drugs (payloads), bound together by linkers, which release the payloads only within cells expressing a unique receptor. The FDA approval of first generation ADCs such as Kadcyla® and Adcetris® has demonstrated the value of these new drug modalities for treating advanced Cancer. ADCs already represent a multi-billion dollar global market. However, it is also evident that opportunities exist for us to improve on these agents and other candidates in development.

    For example, ADCs in general exhibit long circulating half-lives and this has required the use of linker chemistries with high stability at physiological pH in order to minimize toxic side-effects as a result of systemic cleavage. A second class of therapeutic drug conjugates, Small Molecule Drug Conjugates (SMDCs), in general employ similar linkers but have the benefit of shorter systemic exposure since they are cleared from the body more quickly. Unfortunately, SMDCs have yet to produce an approved therapeutic and current clinical candidates employ only one payload molecule per drug conjugate. In addition, ADC and SMDC manufacturers alike have faced challenges in their ability to deliver mixed or multiple drug payloads, and have faced challenges dealing with the heterogeneity of expression of targeted cell surface receptors.

    Our ability to tailor our conjugates in order to mitigate these shortcomings make our TDCs unique and we intend to establish a pipeline that combines many of the best attributes of ADCs and SMDCs, thereby offering a new drug conjugate option for cancer patients.